# GSK1349572 Hepatic Impairment Study

> **NCT01231529** · PHASE1 · COMPLETED · sponsor: **ViiV Healthcare** · enrollment: 16 (actual)

## Conditions studied

- Healthy Subjects
- Hepatic Impairment
- Infection, Human Immunodeficiency Virus
- HIV Infections

## Interventions

- **DRUG:** GSK1349572

## Key facts

- **NCT ID:** NCT01231529
- **Lead sponsor:** ViiV Healthcare
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-11-19
- **Primary completion:** 2011-06-04
- **Final completion:** 2011-06-04
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2019-07-31

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01231529

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01231529, "GSK1349572 Hepatic Impairment Study". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01231529. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*